Australian anti-infective-focused company Reece Pharmaceuticals has entered two of its anti-viral candidates into the University of Melbourne’s The Peter Doherty Institute and The Commonwealth Scientific and Industrial Research Organisation (CSIRO) Covid-19 screening programme.

RECCE327 and REECE529 have been selected by the CSIRO for screening – they have been deemed to be Priority 1 candidates, which means they are deemed to be most likely to have antiviral or antiseptic efficacy against SARS-CoV-2, the virus that causes Covid-19.

Reece non-executive chairman Dr. John Prendergast commented: “We are very pleased to have been selected by the CSIRO, one of the largest and most diverse scientific research organisations in the world, to investigate the efficacy of two of our promising compounds against SARS-CoV-2.

“The compounds’ unique, universal mechanisms of action indicate potential to attack a broad range of viruses and as well, overcome the threat of viruses’ typical hyper-mutation into new and deadly pathogens.”

The aim of the CSIRO and Doherty Institute’s programme is to identify and quickly advance promising anti-virals into R&D for Covid-19. Promising candidates from the screening process will progress into in vitro pre-clinical studies by CSIRO’s pathogens team.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.